Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-line Etoposide Combined With Platinum-based Chemotherapy Followed by Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell Carcinoma - A Randomized, Controlled, Multicenter Phase III Clinical Study

NCT06441344 is registered in ClinicalTrials.gov with Taizhou Hospital as lead sponsor.

NCT NCT06441344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06441344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-line Etoposide Combined With Platinum-based Chemotherapy Followed by Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell Carcinoma - A Randomized, Controlled, Multicenter Phase III Clinical Study
Lead sponsor
Taizhou Hospital
Phase
Phase 3
Overall status
Not yet recruiting
Start date
July 1, 2024
Completion date
May 1, 2030
Enrollment
136 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

maintenance treatment, sclc